
|Articles|August 1, 2003
Rookie Sensations
San Francisco - Accumulating evidence suggests new biologic agents may be used with potential benefit in the management of dermatomyositis, pyoderma gangrenosum, bullous diseases, cutaneous sarcoidosis, and severe atopic dermatitis.Dermatologists, however, have also been looking to use various older therapies in new ways to treat these disabling diseases, Jeffrey P. Callen, M.D., said.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Clascoterone 5% Delivers Strong Phase 3 Hair-Growth Results
2
Alpha-9 Begins First-in-Human Trial of MC1R-Targeted Radiotherapeutic
3
Dermatology Conferences and Meetings Calendar: December 2025
4
ICYMI: First Patient Dosed in Global Phase 2 Study of Oral TYK2 Inhibitor Soficitinib for PN
5


















